537705-06-9

Usage

Uses

Used in Pharmaceutical Industry:
3-METHYL-4-(6-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINE is used as a reactant for the preparation of alkoxypyrazolopyrimidines, which possess inhibitory activity against EGFR (Epidermal Growth Factor Receptor) and erbB2 receptor tyrosine kinase. These activities are significant for the development of targeted therapies against various types of cancer, as they can help regulate cell growth and proliferation, ultimately inhibiting tumor development and progression.
3-METHYL-4-(6-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINE's role in the pharmaceutical industry is crucial, as it contributes to the development of novel and effective treatments for cancer patients. By targeting specific receptors involved in cancer cell growth, alkoxypyrazolopyrimidines derived from 3-METHYL-4-(6-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINE have the potential to offer more precise and less toxic treatments compared to conventional chemotherapy.

Upstream product

• 697299-78-8 2-methyl-5-(2-methyl-4-nitrophenoxy)pyridine 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 13290-74-9 1-chloro-2-methyl-4-nitrobenzene 
• 455-88-9 5-nitro-2-fluorotoluene 

Downstream Products

• 537705-10-5 (6-iodoquinazolin-4-yl)-[3-methyl-4-(6-methylpyridin-3-yloxy)phenyl]amine hydrochloride 
• 537705-05-8 6-iodo-N-(3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)quinazolin-4-amine 
• 848482-94-0 5-fluoro-N-{3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}quinazolin-4-amine 
• 916496-83-8 E-3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-acrylic acid methyl ester 
• 871023-78-8 6-chloro-N-{3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}-5-nitropyrimidin-4-amine hydrochloride 
• 947663-86-7 methyl 4-[[5-formyl-6-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)pyrimidin-4-yl](4-methoxybenzyl)amino]butanoate 
• 892142-99-3 2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy}ethanol 

Relevant academic research and scientific papers

1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS

Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity.

Design, synthesis and biological evaluation of lapatinib derivatives as HER1/HER2 inhibitors

Five Lapatinib derivatives were designed by structurally modifying the side chain as well as the aniline substituent. The ELISA assay showed that the derivatives retained or even improved the inhibitory activity of Lapatinib against HER1/HER2. In vitro cy

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

NOVEL PYRIMIDINE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS

The present invention provides a novel pyrimidine derivative or pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, which can effectively inhibit the growth of cancer cells induced by the overexpression of EGFR incl

Highly functionalised sulfur-based silica scavengers for the efficient removal of palladium species from active pharmaceutical ingredients

The use of multidentate sulfur-based silica scavengers 1,2, and 3 as highly effective adsorbents for the removal of precious metals, specifically palladium residues in this paper, from highly functionalised synthetic intermediates and APIs is described. The synthesis and purification of the polar and electron-rich reaction products, containing multiple functional groups, from palladium-catalysed removals of commonly used protecting groups such as benzyl, benzyloxycarbonyl, and allyloxycarbonyl and Sonogashira, Suzuki, Heck, and Buchwald-Hartwig coupling reactions is reported. The significant levels of residual palladium species, typically associated with these reaction products, are successfully and rapidly removed to below acceptable regulatory levels, of less than 5 ppm, by simple, unoptimised treatment with the designed silica scavengers at room temperature. Performance aspects, including broad solvent compatibility, excellent stability, and high metal affinity, combined with large-scale availability, ease of handling, and minimal loss of API make these silica scavengers particularly useful to process development groups.

PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS

The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

Evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to oncology candidate CP-724,714

The synthesis of the anti-cancer compound 2-methoxy-N-(3-{4-[3-methyl-4-(6- methyl-pyridin-3-yloxy)phenylamino]quinazolin-6-yl}-E-allyl)acetainide (CP-724,714) (1) on multikilogram scale using several different synthetic routes is described. Application of the Sonogashira, Suzuki, and Heck couplings to this synthesis was investigated to identify a safe, environmentally friendly, and robust process for the production of this drug candidate. A convergent and selective synthesis of the candidate was identified which utilizes a Heck coupling of a protected allylamine to install the critical olefin.

SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS

The present invention relates to a compound of Formula (I) and its use in treating hyper-proliferative disorders.

QUINAZOLINE DERIVATIVES

A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.

QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

A quinazoline derivative of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.